ZA202308388B - Nasal compositions comprising alcaftadine - Google Patents

Nasal compositions comprising alcaftadine

Info

Publication number
ZA202308388B
ZA202308388B ZA2023/08388A ZA202308388A ZA202308388B ZA 202308388 B ZA202308388 B ZA 202308388B ZA 2023/08388 A ZA2023/08388 A ZA 2023/08388A ZA 202308388 A ZA202308388 A ZA 202308388A ZA 202308388 B ZA202308388 B ZA 202308388B
Authority
ZA
South Africa
Prior art keywords
alcaftadine
nasal
nasal compositions
methods
pharmaceutically acceptable
Prior art date
Application number
ZA2023/08388A
Other languages
English (en)
Inventor
Sharma Akhilesh
Aware Babasaheb
Shah Viraj
Aiwale Amol
Original Assignee
Alkem Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkem Laboratories Ltd filed Critical Alkem Laboratories Ltd
Publication of ZA202308388B publication Critical patent/ZA202308388B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA2023/08388A 2021-04-01 2023-08-30 Nasal compositions comprising alcaftadine ZA202308388B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202121015680 2021-04-01
PCT/IB2021/055221 WO2022208146A1 (en) 2021-04-01 2021-06-14 Nasal compositions comprising alcaftadine

Publications (1)

Publication Number Publication Date
ZA202308388B true ZA202308388B (en) 2025-11-26

Family

ID=76523258

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2023/08388A ZA202308388B (en) 2021-04-01 2023-08-30 Nasal compositions comprising alcaftadine

Country Status (12)

Country Link
US (6) US20240173331A1 (https=)
EP (1) EP4312973A1 (https=)
JP (1) JP2024512121A (https=)
KR (1) KR20230163413A (https=)
CN (1) CN117120029A (https=)
AU (1) AU2021437358A1 (https=)
BR (1) BR112023019795A2 (https=)
CA (1) CA3213156A1 (https=)
CL (1) CL2023002871A1 (https=)
MX (1) MX2023011546A (https=)
WO (1) WO2022208146A1 (https=)
ZA (1) ZA202308388B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240173331A1 (en) * 2021-04-01 2024-05-30 Alkem Laboratories Limited Nasal compositions comprising alcaftadine
CN114504037B (zh) * 2022-01-14 2024-12-03 云南中茶茶业有限公司 一种茶叶发酵瓶用出瓶机
US11992493B1 (en) * 2022-10-25 2024-05-28 Liangdan Sun Use of compound or pharmaceutical derivative thereof in inhibiting CaMK2G protein activity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3877904D1 (de) 1987-11-13 1993-03-11 Asta Pharma Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge.
IL101850A (en) 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv 11-(4-Piperidinyl)-imidazo (2,1-b) (3) benzazepine derivatives their preparation and pharmaceutical compositions containing them
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
PL1919450T3 (pl) 2005-09-01 2014-11-28 Meda Ab Kompozycja liposomowa zawierająca lek przeciwhistaminowy i kortykosteroid oraz jej zastosowanie do wytwarzania leku do leczenia nieżytu nosa i chorób spokrewnionych
BRPI0710085B8 (pt) * 2006-03-31 2021-05-25 Vistakon Pharmaceutical Llc composições oftálmicas e seus kits
CA2840731A1 (en) * 2011-06-29 2013-01-03 Allergan, Inc. Alcaftadine for use in the treatment of urticaria
CN102283849A (zh) 2011-06-29 2011-12-21 北京阜康仁生物制药科技有限公司 一种含有阿卡他定的药物组合物
WO2019022225A1 (ja) 2017-07-28 2019-01-31 参天製薬株式会社 アルカフタジン又はその塩を含有する水性医薬組成物
WO2021255622A1 (en) * 2020-06-15 2021-12-23 Alkem Laboratories Limited Combination of alcaftadine and a corticosteroid
US20240173331A1 (en) * 2021-04-01 2024-05-30 Alkem Laboratories Limited Nasal compositions comprising alcaftadine

Also Published As

Publication number Publication date
US20250064825A1 (en) 2025-02-27
KR20230163413A (ko) 2023-11-30
MX2023011546A (es) 2023-10-06
US12274702B2 (en) 2025-04-15
US20240173331A1 (en) 2024-05-30
US20250064827A1 (en) 2025-02-27
BR112023019795A2 (pt) 2023-11-07
EP4312973A1 (en) 2024-02-07
US20260007682A1 (en) 2026-01-08
US20250064826A1 (en) 2025-02-27
WO2022208146A1 (en) 2022-10-06
JP2024512121A (ja) 2024-03-18
CA3213156A1 (en) 2022-10-06
US20250064828A1 (en) 2025-02-27
AU2021437358A1 (en) 2023-09-14
CN117120029A (zh) 2023-11-24
CL2023002871A1 (es) 2024-01-26

Similar Documents

Publication Publication Date Title
ZA202308388B (en) Nasal compositions comprising alcaftadine
ZA202212128B (en) Combination of alcaftadine and a corticosteroid
SA519402405B1 (ar) مركبات مثبط فيروس نقص المناعة البشري
ZA202204929B (en) Rimegepant for cgrp related disorders
PH12021552881A1 (en) Amino quinazoline derivatives as p2x3 inhibitors
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
EP4609866A3 (en) Oxysterols and methods of use thereof
EA202191188A1 (ru) Бензамиды производных пиразолил-амино-пиримидинила, композиции на их основе и способы применения
EA202191239A1 (ru) Соединения и их применение для лечения дефицита 1-антитрипсина
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
MX2024004725A (es) Metodos novedosos.
WO2016168553A8 (en) Deuterated obeticholic acid
ZA202204907B (en) Orally disintegrating pharmaceutical compositions of apixaban
SA521421098B1 (ar) -h4 مركبات بيريدو بيريميدينات كمثبطات مستقبل هستامين
MX2019014321A (es) Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
NZ744942A (en) Compositions and methods for treating nasal and paranasal mucosa diseases with nicotinic acetylcholine receptor agonists
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
MX2023005801A (es) Derivados de ftalazina como inhibidores de purinoceptor 3 de p2x (p2x3).
MX2023005805A (es) Derivados de 4-aminas de (aza)quinolina como inhibidores del purinorreceptor 3 p2x (p2x3).
MY189372A (en) Indole derivatives
MX2021015441A (es) Formas cristalinas de cabotegravir de sodio.
EA202091561A1 (ru) Фармацевтическая композиция, содержащая фармацевтически приемлемую кислотно-аддитивную соль леналидомида
EA201890789A1 (ru) Содержащая цинеол композиция для лечения заболеваний носа
PH12020551620A1 (en) Compositions for preventing or treating dry eye